Breakthrough Phase 2 Trial Results Show Promise for Patients Ineligible for Standard Reperfusion TherapiesData Presented at International Stroke ConferenceData Show That LT3001 Delivers Meaningful ...
Global phase 3 OCEANIC-STROKE randomized 12,327 patients to asundexian 50 mg daily vs placebo on background antiplatelets, with follow-up to 31 months. Treatment effects were consistent across TOAST ...
For infants and toddlers who have had a stroke, a new treatment that restricted the use of their stronger arm and hand to encourage them to use their stroke-affected arm and hand, combined with ...
For patients with noncardioembolic ischemic stroke or high-risk transient ischemic attack, asundexian, a factor XIa inhibitor, reduced risk for secondary stroke with no excess risk for any bleeding vs ...
Experts at ISC 2026 highlighted growing evidence that GLP-1 receptor agonists may reduce stroke risk and support brain health ...
An investigational anti-clotting medication, asundexian, demonstrated a reduction in the risk of a second ischemic ...
The factor XIa inhibitor asundexian reduced recurrent ischemic stroke without increasing major or minor bleeding in patients ...
A bulge caused by a neck artery tear doesn’t raise stroke risk in the first six months after diagnosis, suggesting fewer follow-up scans are safe for patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results